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ABSTRACT
Sixty patients were randomized to receive intravenous busulfan (iBU) either as 0.8 mg/kg, over 2 hours 4 times
a day (BU4 arm) or 3.2 mg/kg, over 3 hours once a day (BU1 arm) in conditioning therapy for hematopoietic
cell transplantation. The complete pharmacokinetic parameters for the first busulfan dose were obtained from
all patients and were comparable between the 2 arms: for the BU4 and BU1 groups, elimination half-life (mean 
SD) was 2.75  0.22 versus 2.83  0.21 hours, estimated daily AUC was 6058.0  1091.9 versus 6475.5 
1099.4 M·min per day, and clearance was 2.05  0.36 versus 1.91  0.31 mL/min/kg, respectively. Times to
engraftment after transplantation were similar between the 2 arms. No significant differences were evident in
the occurrence of acute graft-versus-host disease (aGVHD) and hepatic veno-occlusion disease (VOD).
Moreover, other toxicities observed within 100 days after transplantation were not significantly different
between the 2 arms. The cumulative incidence of nonrelapse mortality was 20.8% in BU4 arm and 13.3% in
BU1 arm. In conclusion, our randomized study demonstrates that the pharmacokinetic profiles and posttrans-
plant complications are similar for once-daily iBU and traditional 4-times-daily iBU.
© 2007 American Society for Blood and Marrow Transplantation
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Busulfan, a bifunctional alkylating agent with po-
ent toxicity against hematopoietic cells, is a common
omponent of high-dose conditioning regimens for
ematopoietic cell transplantation (HCT) [1-3].
usulfan-based conditioning regimens are excellent
lternatives to those involving total-body irradiation
4-8]. However, until recently, busulfan has only been
vailable in the oral form. The efﬁcacy of oral busul-
an is frequently compromised by variable bioavail-
bility and unpredictable systemic exposure over the
ourse of treatment, largely because of the erratic
bsorption of oral agents and frequently complicated
mesis [9,10]. Variations in systemic busulfan concen- aration may lead to overdosing, which has a higher risk
f toxicity [9,11,12], or underdosing, which may result
n graft failure or suboptimal antitumor activity
13,14]. In addition, intestinal absorption of busulfan
ay contribute to hepatic veno-occlusive disease
VOD) via a hepatic ﬁrst-pass effect [15].
To avoid the inherent problems of oral administra-
ion and improve the accuracy of dosing, several formu-
ations of intravenous busulfan have been developed in
imethyl sulfoxide [9], N,N-dimethylacetamide and
olyethylene glycol 400 (Busulfex®, Orphan Medical,
innetonka, MN) [16], liposomes [17], and microc-
ystalline lipids [18]. Busulfex®, the only currently
vailable formulation, consists of a stable dissolved
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S.-G. Ryu et al.1096rug that can be diluted further, either in normal
aline or 5% dextrose in water, and delivered paren-
erally with 100% bioavailability [16]. A phase I trial
howed that an intravenous busulfan dose of 0.8 mg/
g, yielded similar pharmacokinetic parameters to a
tandard oral dose of 1 mg/kg, [19]. The pharmaco-
inetic data were supported by a phase II trial in which
atients with advanced hematologic malignant disease
ere treated with 16 doses of intravenous busulfan
0.8 mg/kg) every 6 hours, followed by 2 daily doses of
ntravenous cyclophosphamide (60 mg/kg) [20]. This
egimen was also well tolerated, conﬁrming the safety
nd efﬁcacy of the drug at the dose. Moreover, intra-
enous busulfan displays a more consistent dosing and
harmacokinetic proﬁle than oral busulfan. Parenteral
usulfan formulations reduce hepatic sinusoidal expo-
ure, decrease (but not altogether eliminate) interpa-
ient variability in systemic exposure, and exclude dos-
ng uncertainties associated with emesis. The 2-fold
ange of the area under the curve (AUC) following
dministration of intravenous busulfan is as narrow as
hat achievable by targeted oral dosing of busulfan
lus therapeutic monitoring [11].
Although most alkylating agents are administered
n a daily basis, in oral clinical trials, busulfan dosage
as divided into 4 times per day to improve patient
ompliance, because of the sole availability of 2 mg
ablets [21]. Consequently, most intravenous busulfan
ormulations have been administered as 4-times-daily
osing [22]. A once-daily dosage regimen of busulfan
ould be more convenient and tolerable than divided
osing. Preclinical data on busulfan treatment on a
nce-daily basis are available in animal models [23]. In
hildren, busulfan was administered orally as a daily
ose with no observed increase in toxicity [24]. Several
ingle-arm studies additionally suggest that once-daily
r twice-daily intravenous busulfan regimens are
qually safe and effective, compared to the traditional
-times-daily intravenous dosage [21,25,26].
In this study, we perform a prospective random-
zed trial of 4-times-daily versus once-daily dosing of
ntravenous busulfan (Busulfex®, Orphan Medical,
innetonka, MN) in conditioning therapy for HCT.
harmacokinetic characteristics of intravenous busul-
an and clinical outcomes in terms of engraftment,
omplications, nonrelapse mortality, and overall sur-
ival are compared between the 2 administration
chedules.
ATIENTS AND METHODS
atients
Adult patients (15 years or older), who received
ntravenous 3.2 mg/kg/day busulfan on the ﬁrst day of
onditioning therapy for HCT, were included in this
tudy. No other chemotherapeutic drugs were allowed en that day. A Karnofsky performance score of 70 or
igher, and adequate cardiac, hepatic, and renal func-
ions were required.
rotocol Outline and Randomization
This study was approved by the institutional re-
iew board of the Asan Medical Center. Patients pro-
ided informed consent before randomization. Pa-
ients were randomly assigned the 4-times-daily
ntravenous busulfan (BU4 arm) or once-daily intra-
enous busulfan (BU1 arm) treatment regimen. We
mployed the block randomization method using ran-
om number tables, including stratiﬁcation according
o the conditioning regimen (busulfan-cyclophospha-
ide [BuCy] versus busulfan-ﬂudarabine-antithymo-
yte globulin [BuFluATG] versus busulfan only [Bu]).
usulfan was diluted in normal saline to 0.5 mg/ml,
nd infused by pump through a central venous cath-
ter. Patients from the BU4 arm received intravenous
usulfan (0.8 mg/kg) over 2 hours, 4 times a day, and
hose from the BU1 arm received it as 3.2 mg/kg over
hours once a day. All doses of busulfan were calcu-
ated using (1) actual body weight (ABW) if less than
r equal to ideal body weight (IBW), (2) IBW if ABW
asmore than, but within 120% of IBW, or (3) “IBW
.40 * (ABW  IBW)” if ABW exceeded IBW by
120%.
For the BuCy regimen, intravenous busulfan (3.2
g/kg/day) was administered on days 7 to 4 and
yclophosphamide (60 mg/kg/day) on days 3 and 2.
he time between the last dose of busulfan and the ﬁrst
ose of cyclophosphamide was 14 hours in the BU4 arm
nd 27 hours in the BU1 arm. For the BuFluATG
egimen, we administered intravenous busulfan (3.2 mg/
g/day) for 2 days (days 7 and 6), ﬂudarabine (30
g/kg) for 6 days (days 7 to 2), and antithymocyte
lobulin. Patients received 1 of 2 types of antithymocyte
lobulin according to availability in Korea, speciﬁcally,
abbit antithymocyte globulin (Thymoglobulin®, IMTIX-
ANGSTAT, Lyon, France; 1.5 mg/kg/day on days
4 to 2 with a matched sibling donor, 3.0 mg/kg/
ay on days 4 to 2 with an unrelated donor, and
.0 mg/kg/day on days 4 to 1 with a haplo-iden-
ical familial donor; n  24) or horse antithymocyte
lobulin (Lymphoglobulin®, IMTIX-SANGSTAT,
yon, France; 7.5 mg/kg/day on days 4 to 2 with
matched sibling donor, 15.0 mg/kg/day on days 4
o 2 with an unrelated donor, and 15.0 mg/kg/day
n days 4 to 1 with a haplo-identical familial
onor; n  8). One patient received 20 mg alemtu-
umab (MabCampath®, Schering, Berlin, Germany)
n day 7, because of the unavailability of antithy-
ocyte globulin in Korea at that time. For the Bu
egimen, intravenous busulfan (3.2 mg/kg/day) was
dministered on days 6 to 3. The Bu regimen was
mployed speciﬁcally for autologous HCT.
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Four-Times Daily versus Once-Daily Intravenous Busulfan 1097ransplantation Procedure
All patients received an intravenous loading dose
f phenytoin (15 mg/kg) the day before the ﬁrst busul-
an administration, and oral dosing was continued to
aintain therapeutic levels (10 to 20 mg/L) until the
ay after the last dose of busulfan. Ciproﬂoxacin and
cyclovir were administered for gut decontamination
nd viral prophylaxis, respectively. Hyperhydration
nd mesna were given to patients receiving the BuCy
egimen for the prevention of cyclophosphamide-in-
uced hemorrhagic cystitis. All cellular blood prod-
cts were leukocyte-depleted and irradiated prior to
ransfusion. For patients undergoing allogeneic HCT,
mmunoglobulin (500 mg/kg) was administered intra-
enously on day 7, every other week until day 120,
nd monthly until day 180. Prophylactic therapy for
raft-versus-host disease (GVHD) comprised cyclo-
porine alone in acute leukemia patients undergoing
atched sibling donor HCT after conditioning treat-
ent with the BuCy regimen, or cyclosporine plus
ethotrexate in other patients. Cyclosporine (1.5 mg/
g) was given intravenously every 12 hours starting on
ay 1, and then orally once oral intake became
easible. Intravenous methotrexate was administered
t a dose of 15 mg/m2 on day 1 and 10 mg/m2 on days
, 6, and 11. The day 11 dose was omitted for patients
onditioned with the BuFluATG regimen for
atched sibling donor HCT. Heparin was adminis-
ered to patients receiving the BuCy or Bu regimen at
rate of 100 units/kg/day from day 7 to day 20, but
iscontinued in case clinically signiﬁcant bleeding was
bserved or if the activated partial thromboplastin
ime (aPTT) exceeded the upper limit of control by
.2 times.
Hematopoietic cell grafts were infused on day 0
for bone marrow) or days 0 and 1 (for granulocyte-
olony stimulating factor [G-CSF] mobilized periph-
ral mononuclear cells) without T cell depletion. All
atients received intravenous G-CSF (450 g, once
aily), commencing on day 5, until the peripheral
lood absolute neutrophil counts were over 3000/L.
onitoring of Patients
All patients were prospectively monitored for en-
raftment and posttransplant toxicities, including
VHD, hepatic VOD, and infections. Blood was
ithdrawn daily for complete counting, such as reticu-
ocyte counts. Blood chemistry and electrolytes, in-
luding the magnesium level, were determined twice
eekly or more frequently if necessary, whereas pro-
hrombin time (PT) and aPTT were measured
eekly.
The ﬁrst day with an absolute neutrophil count
500/L for 2 consecutive days was recorded for
one marrow engraftment. Patients who did not dis-
lay absolute neutrophil counts of 500/L for 2 consecutive days after HCT were categorized as “pri-
ary graft failure.” Patients with initial engraftment
n whom absolute neutrophil counts subsequently de-
lined to 500/L were classiﬁed as secondary graft
ailure (if they survived for at least 21 days). The ﬁrst
ay of unsupported platelet counts 20,000/L for 7
onsecutive days was additionally recorded. Hemato-
oietic chimerism was evaluated in all allogeneic
ransplant patients, using peripheral blood samples
rom the donor and recipient, by PCR of short tan-
em repeats or amelogenin loci [27]. After transplan-
ation, recipient peripheral blood samples were with-
rawn monthly for the ﬁrst 3 months, followed by
very 3 months for an additional 1-2 years or until
eath. Complete donor chimerism was deﬁned as the
resence of only donor type hematopoietic cells after
llogeneic HCT. Mixed chimerism was deﬁned as the
oexistence of both recipient and donor hematopoietic
ells after allogeneic HCT. The degree of mixed chi-
erism was measured as the proportion of recipient
ells in a given sample, and determined by the pro-
ortion of peak areas corresponding to recipient sig-
als, compared to the sum of peak areas of donor and
ecipient signals.
Acute GVHD (aGVHD) was diagnosed on the
asis of clinical symptoms, laboratory tests, and when-
ver possible, histopathologic ﬁndings of the skin, oral
ucosa, and gastrointestinal tract [28], and classiﬁed
ccording to clinical criteria [29]. Hepatic VOD was
iagnosed in patients displaying at least 2 of the fol-
owing before day 30: (1) hyperbilirubinemia (biliru-
in 2.0 mg/dL), (2) painful hepatomegaly, and (3)
nexplained weight gain (2% from baseline) [30],
ith no other explanations for these signs and symp-
oms at the time of diagnosis. VOD was classiﬁed as
ild, moderate, or severe [31]. Cytomegalovirus
CMV) infection was monitored weekly using shell
ial culture [32] and CMV antigenemia assay [33,34].
treatment schedule of 5 mg/kg ganciclovir every 12
ours was initiated in patients displaying CMV infec-
ion or disease.
harmacokinetic Studies
For pharmacokinetic studies, blood samples (5 mL)
ere obtained from all patients at 5 time points. This
imited sampling strategy was adopted from a previous
tudy [35]. Blood samples were obtained from patients
n the BU4 arm at target time points of 2.5, 3, 4, 5, and
hours after the start of infusion, and 3.5, 5, 6, 7, and
2 hours after the start of the infusion in BU1 pa-
ients. Sampling was performed with the ﬁrst dose
nly. Samples were taken from a peripheral vein into
rechilled heparin tubes, with plasma separation
ithin 30 minutes. Plasma was separated by centrifu-
ation at 2500 rpm for 10 minutes at 4°C placed in
ryogenic vials, and stored at 40°C until analysis by
v
s
q
t
c
d
H
I
c
v
c
a
n
i
m
c
l
t
c
n
f
d
c
a
a
9
d
2
c
o
v
p
p
d
b
v
t
c
ﬁ
c
n
v
S
n
w
g
H
t
w
C
T
c
d
p
a
p
c
v
T
a
h
i
t
r
p
s
e
a
v
a
R
P
b
a
b
g
f
(
b
a
t
p
1
s
i
(
w
c
p
b
d
A
t
a
H
f
p
3
s
5
d
S.-G. Ryu et al.1098alidated liquid chromatography with tandem mass
pectrometry (LC-MS/MS) on the API 3000 triple
uadruple mass spectrometer equipped with an elec-
rospray ion source (MDS SCIEX, South San Fran-
isco, CA). An aliquot of the sample (20 L) was
elivered into the electrospray ion source using
PLC (Agilent 1100 series, Agilent Technologies
nc., Santa Clara, CA) with a C18 Capcell Pak MG
olumn (2.0  50 mm, 3.0 m particle size). For
alidation procedures, plasma calibration curves, each
onsisting of 6 levels of busulfan (30-6000 ng/mL) and
ﬁxed concentration of the internal standard (500
g/mL, were prepared and assayed. To assess the
ntra- and interday precision and accuracy of the
ethod, 5 replicates of the plasma standards at 3
oncentrations (40, 400, and 4000 ng/mL) were ana-
yzed. The calibration curves were linear throughout
he concentration ranges examined, with correlation
oefﬁcients 0.998 for all cases. Based on a signal-to-
oise level of 10, the limit of quantiﬁcation for busul-
an was found to be 30 ng/mL. Using the percentage
eviation of the mean from the true value and the
oefﬁcient of variation (CV) as measures of accuracy
nd precision, respectively, the intra- and interday
ccuracy were determined to be 94.10-107.80% and
5.59-101.44%, respectively, and the intra- and inter-
ay precision were determined to be 3.82-6.29% and
.42-10.14%, respectively, with 5 replicates at each
oncentration level.
The busulfan peak concentrations (Cmax) are the
bserved values. Pharmacokinetic parameters, such as
olume of distribution (Vd), half-life, and busulfan
lasma clearance, were derived from a 1-compartment
harmacokinetic model. The AUC value per busulfan
ose was calculated by dividing the drug dose by the
usulfan plasma clearance estimate. The daily AUC
alue in the BU4 arm was estimated as 4-fold that of
he AUC for the ﬁrst dose, since previous studies
onsistently demonstrate that pharmacokinetic pro-
les of the ﬁrst dose can be used as a predictor of later
oncentrations of the drug [21,25,26]. Pharmacoki-
etic modeling was performed using WinNonlin®
5.0.1 (Pharsight Corporation, Mountain View, CA).
tatistical Analysis
This was designed as a prospective, randomized,
onblind study. The primary endpoints of the study
ere the pharmacokinetic parameters, occurrence of
rade III or higher toxicity within 100 days after
CT, and cumulative incidence of nonrelapse mor-
ality. Toxicities observed within 100 days after HCT
ere graded according to NCI Common Toxicity
riteria v2.0, and classiﬁed between grades I and VI.
oxicities categorized as grades III to VI were re-
orded as severe. In addition, acute GVHD, CMV (isease or infection, interstitial pneumonitis, and he-
atic VOD were recorded separately.
Between-arm differences in baseline patient char-
cteristics, occurrence of posttransplant toxicity, and
harmacokinetic parameters were compared by the
hi-square test or Fisher’s exact test for categoric
ariables, and Student t-test for continuous variables.
his study included different conditioning regimens
nd we performed the Breslow-Day test to exclude
eterogeneity of odds ratio for posttransplant toxicity
n different conditioning regimens. If the test accepts
he null hypothesis of the homogeneity of the odds
atio (P .05), it is possible to compare the posttrans-
lant toxicity by a single odds ratio using the chi-
quare or Fisher’s exact tests. Cumulative incidence of
ngraftment and nonrelapse mortality were calculated
nd compared with Gray’s method [36]. Overall sur-
ival was estimated with the Kaplan-Meier method,
nd compared using a long-rank test.
ESULTS
atient Characteristics
In total, 60 patients were enrolled into the study
etween May 2004 and August 2005. We randomly
ssigned 30 patients to the 4-times-daily intravenous
usulfan group (BU4 arm) and 30 to the once-daily
roup (BU1 arm). As of July 15, 2006, the median
ollow-up duration of surviving patients was 511 days
range: 299-736 days).
The distribution of patients was well balanced
etween the treatment groups with regard to patient
nd donor characteristics (Table 1), and transplanta-
ion procedure (Table 2). The median age of the 60
atients (23 women, 37 men) was 37.5 years (range:
6-58 years). Acute nonlymphoblastic leukemia, ob-
erved in 58% of the patients, was the most common
ndication for HCT. At the time of HCT, 17 patients
28.3%) displayed high-risk features, speciﬁcally, 10
ith acute leukemia beyond ﬁrst remission, 3 with
hronic myeloid leukemia beyond the ﬁrst chronic
hase, and 4 with myelodysplastic syndrome having
one marrow blasts 5%. The median time from
iagnosis to HCT was 185 days (range: 6-2399 days).
ll patients except 2, who received autologous hema-
opoietic cell grafts, underwent allogeneic HCT. The
llogeneic hematopoietic cell graft donor was an
LA-matched sibling in 31 cases, a haploidentical
amily member in 6, and an unrelated volunteer in 21
atients. The median age of allogeneic donors was
6.0 years (range: 18-70 years). The donor-recipient
ex pair was female to male in 15 (25.9%) cases, and
0% of the patients were ABO-mismatched with their
onor.
The BuCy conditioning regimen was applied to 25
41.7%), BuFluATG to 33 (55.0%) and Bu to 2 (3.3%)
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Four-Times Daily versus Once-Daily Intravenous Busulfan 1099atients. The immunosuppressive regimen for
VHD prophylaxis was cyclosporine alone in 15
25.9%) and cyclosporine plus methotrexate in 43
74.1%) patients. The hematopoietic cell graft was
one marrow in 36 (60.0%) and G-CSF mobilized
eripheral mononuclear cells in 24 (40.0%) patients.
he median mononuclear cell dose was 1.1  108/kg
range: 0.3-16.2  108/kg) and median CD34 cell
ose was 5.3  106/kg (range: 1.0-125  106/kg).
harmacokinetic Parameters
A complete pharmacokinetic proﬁle was obtained
rom all 60 patients. Parameters are shown in Table 3.
he pharmacokinetic studies indicate that intravenous
usulfan presents predictable linear kinetics with little
ariability in both arms (Figure 1). There were no
igniﬁcant differences between the BU4 and BU1
roups regarding Vd (mean [CV], 0.48 L/kg [12.5%]
ersus 0.46 L/kg [10.9%], P  .187), clearance (mean
CV], 2.05 mL/min/kg [17.6%] versus 1.90 mL/
able 1. Patient and Donor Characteristics
BU4 arm
(n  30)
BU1 arm
(n  30) P
ge, years
35 or less 15 (50.0%) 14 (46.7%) .796
>35 15 (50.0%) 16 (53.3%)
ex
Male 17 (56.7%) 20 (66.7%) .426
Female 13 (43.3%) 10 (33.3%)
iagnosis
AML/acute mixed leukemia 16 (53.3%) 19 (63.3%) .372
ALL 3 (10.0%) 3 (10.0%)
CML 5 (16.7%) 3 (10.0%)
MDS 3 (10.0%) 5 (16.7%)
Miscellaneous 3 (10.0%) 0 (0.0%)
isease status at HCT
Standard risk 23 (76.7%) 20 (66.7%) .390
High risk 7 (23.3%) 10 (33.3%)
ime from diagnosis to HCT,
days
180 or less 13 (43.3%) 15 (50.0%) .605
>180 17 (56.7%) 15 (50.0%)
ype of graft donor
Autologous 1 (3.3%) 1 (3.3%) .862
Matched sibling 15 (50.0%) 16 (53.3%)
Haplo-identical familial 4 (13.3%) 2 (6.7%)
Unrelated 10 (33.3%) 11 (36.7%)
onor age, years
35 or less 15 (51.7%) 11 (37.9%) .291
>35 14 (48.3%) 18 (62.1%)
ex pair (donor-recipient)
Female-male 9 (31.0%) 6 (20.7%) .368
Other 20 (69.0%) 23 (79.3%)
onor-recipient ABO
incompatibility
No 15 (51.7%) 14 (48.3%) .793
Yes 14 (48.3%) 15 (51.7%)
ML indicates acute myelogenous leukemia; ALL, acute lympho-
blastic leukemia; CML, chronic myeloid leukemia; HCT, he-
matopoietic cell transplantation. *in/kg [16.3%], P  .113), and half-life (mean [CV]
.75 hours [8.0%] versus 2.83 hours [7.4%], P .180).
ean values of Cmax and AUC of the BU1 arm
4217.6 ng/mL and 6475.5 M·min) were about 4
imes those of the BU4 arm (1064.6 ng/mL and
514.5 M·min). Thus, the estimated daily AUC
alue was equivalent between the BU4 and BU1 arms
mean [CV], 6058.0 M·min [18.0%] versus 6475.5
M·min [17.0%], P  .145). The range of estimated
UC values was 4179.3 to 8196.5 M·min (median
923.6 M·min) in BU4 patients and 4347.0 to 8957.4
M·min (median 6378.4 M·min) in BU1 patients.
ngraftment Data and Major Early
osttransplant Toxicities
No signiﬁcant differences between the treatment
roups were evident with regard to time to absolute
eutrophil counts 500/L, unsupported platelet
able 2. Transplantation Procedure
BU4 arm
(n  30)
BU1 arm
(n  30) P
onditioning regimen
Busulfan-cyclophosphamide 12 (40.0%) 13 (43.3%) .965
Busulfan-fludarabine-ATG 17 (56.7%) 16 (53.3%)
Busulfan 1 (3.3%) 1 (3.3%)
VHD prophylaxis
No 1 (3.3%) 1 (3.3%) .667
Cyclosporine only 6 (20.0%) 9 (30.0%)
Cyclosporine plus
methotrexate 23 (76.7%) 20 (66.7%)
issue for grafts
Bone marrow 17 (56.7%) 19 (63.3%) .598
Peripheral blood 13 (43.3%) 11 (36.7%)
ononuclear cell dose, 108/kg
1.0 or less 12 (40.0%) 17 (56.7%) .196
>1.0 18 (60.0%) 13 (43.3%)
D34 cell dose, 106/kg
3.0 or less 6 (20.0%) 8 (26.7%) .542
>3.0 24 (80.0%) 22 (73.3%)
CT indicates hematopoietic cell transplantation; GVHD, graft-
versus-host disease; ATG, antithymocyte globulin.
able 3. Pharmacokinetic Parameters Based on the Administration
chedule
BU4 arm
(n  30)
BU1 arm
(n  30) P*
olume of
distribution (L/kg) 0.48  0.06 0.46  0.05 .187
learance
(mL/min/kg) 2.05  0.36 1.90  0.31 .113
alf-life (hour) 2.75  0.22 2.83  0.21 .180
max (ng/mL) 1064.6  147.2 4217.6  700.1 <.001
UC (M·min) 1514.5  273.0 6475.5  1099.4 <.001
stimated daily
AUC (M·min) 6058.0  1091.9 6475.5  1099.4 .145
UC indicates area under the curve.
ean  SD.Student’s t-test.
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S.-G. Ryu et al.1100ounts 20,000/L, and reticulocyte count 1%, oc-
urrence of secondary graft failure, achievement of
omplete donor chimerism 4 weeks and 100 days after
CT, transfusion requirements within 100 days after
CT, and duration of G-CSF administration (Table 4).
umulative incidence of acute GVHD among pa-
igure 1. Busulfan concentration curves of the BU4 and BU1
roups.
able 4. Engraftment Data and Major Early Posttransplant Toxicities
ngraftment
Number of patients achieving ANC >500/L
Median days to ANC >500/L (range)
Secondary graft failure
Number of patients achieving platelet >20,000/L
Median days to platelet > 20,000/L
Number of patients achieving reticulocyte count >1%
Median days to reticulocyte count >1%
omplete donor chimerism (%)
4 weeks after HCT
100 days after HCT
ransfusion requirements within 100 days after HCT
Red blood cells, units, mean  SD
Platelets,* units, mean  SD
uration of G-CSF administration, days Mean  SD
cute GVHD
Cumulative incidence
Grade 1
Grade 2
Grade 3
Grade 4
MV infection within 100 days after HCT
MV disease
epatic VOD
Mild
Moderate
Severe
NC indicares absolute neutrophil count; HCT, hematopoietic c
stimulating factor; GVHD, graft-versus-host disease; VOD, ven
One unit of single donor pheresis was calculated as 6 units of ran
Chi-square test.
Gray’s method.
Student’s t-test.ients receiving allogeneic HCT was 31.0% in the
U4 arm and 13.8% in the BU1 arm (P  .145).
MV infection occurred in 12 BU4 (40.0%) and 7
23.3%) BU1 (P  .165) patients, but did not develop
o CMV disease. Three patients (10.0%) of the BU4
rm and 5 (16.7%) of the BU1 arm developed hepatic
OD (P  .448). No severe VOD was evident.
CI Grading of Toxicities within 100 Days
f Allogeneic BMT
Toxicity occurrence was investigated within 100
ays after HCT, and graded according to NCI Com-
on Toxicity Criteria v2.0 (Table 5). Severe pulmo-
ary, renal, cardiovascular, and neurologic toxicity
ccurred infrequently on both arms, whereas severe
etabolic abnormalities and infectious complications
ere frequently observed. Three patients in each arm
eveloped severe neurologic toxicity, all of which oc-
urred after 30 days posttransplantation. There were
o signiﬁcant differences between treatment groups
ith regard to the frequencies of severe toxicity, ex-
ept nausea/vomiting and diarrhea. Speciﬁcally, the
requency of nausea/vomiting was higher (30.0% ver-
BU4 arm
(n  30)
BU1 arm
(n  30) P
29 30 .313†
14 (10-24) 14 (10-29) .872‡
1 3 .317†
26 26 1.000†
6.5 (13-114) 25.5 (13-144) .946‡
23 27 .166†
30 (13-602) 26 (14-595) .216‡
/27 (92.6%) 26/29 (89.7%) .700†
/23 (95.7%) 20/22 (90.9%) .524†
12.4  9.6 11.8  12.2 .845§
24.0  101.7 140.2  146.1 .909§
12.3  4.2 13.4  6.6 .443§
9/27 5/28
31.0% 13.8% .145‡
2 0
4 2
2 0
1 3
12 (40.0%) 7 (23.3%) .165†
0 0
3 (10.0%) 5 (16.7%) .448†
1 3
2 2
0 0
splantation; SD, standard deviation; G-CSF, granulocyte colony
usive disease.
nor platelet concentrates.2
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ersus 13.3%, P .038) in the BU4 arm than the BU1
rm.
onrelapse Mortality and Overall Survival
Of the 60 patients analyzed, 23 deaths have been
ecorded (11 in the BU4 arm and 12 in the BU1 arm).
verall survival at 1 year was 69.0% in the BU4 arm
nd 70.0% in the BU1 arm (P  .758; Figrue 2).
leven of the 23 deaths were related to relapse of
able 5. NCI Grading of Toxicities within 100 Days after Allogeneic B
BU4 arm
ulmonary toxicities, grade III-IV
epatic toxicities, grade III-IV 13 (
Aspartate aminotransferase, increase 8 (
Alanine aminotransferase, increase 12 (
Bilirubin, increase 3 (
enal toxicities, grade III-IV
Renal failure
oagulation abnormalities, grade III-IV 11 (
aPTT prolongation 3 (
Disseminated intravascular
coagulation 7 (
Thrombotic microangiopathy
ardiovascular toxicities, grade III-IV 3 (
Arrhythmia 1 (
Hypertension 1 (
Other 1 (
astrointestinal toxicities, grade III-IV 12 (
Stomatitis 4 (
Nausea/vomiting 9 (
Diarrhea
leeding complications, grade III-IV 4 (
CNS bleeding 1 (
Epistaxis 1 (
Gastrointestinal bleeding 2 (
Hematuria 2 (
etabolic abnormalities, grade III-IV 22 (
Hypercalcemia
Hyperglycemia 13 (
Hypernatremia
Hyperkalemia 2 (
Hypermagnesemia 1 (
Hypocalcemia 2 (
Hypophosphatemia 14 (
Hypoglycemia 1 (
Hyponatremia 14 (
Hypokalemia 13 (
Hypomagnesemia 1 (
eurologic toxicities, grade III-IV 3 (
Decrease of consciousness 3 (
Seizure
Other 1 (
nfectious complications, grade III-IV 23 (
Febrile neutropenia 14 (
Infection with neutropenia 18 (
Infection without neutropenia 23 (
Other 17 (
reslow-Day tests showed the homogeneity of the odds ratio for p
Chi-square test.
Fisher’s exact test.nderlying disease, whereas the remaining 12 were tonrelapse deaths (7 BU4 and 5 BU1 patients). Cu-
ulative incidence of nonrelapse mortality at 2 years
as 20.8% in the BU4 arm and 13.3% in the BU1 arm
P  .488; Figure 3). Nonrelapse deaths were caused
y bleeding (n  1; posttransplant day 24 [D24]),
nfection (n  2; D41, D47), GVHD (n  3; D62,
237, D335) and hepatic failure of unknown etiology
n  1; D453) in the BU4 arm, and graft failure (n 
; D60, D70) and GVHD (n 3; D60, D62, D371) in
he BU1 arm. Because all but 2 patients received 1 of
30) BU1 arm (n  30) P
0 —
14 (46.7%) .795*
5 (16.7%)
12 (40.0%)
5 (16.7%)
1 (3.3%) 1.000†
1 (3.3%)
6 (20.0%) .152*
1 (3.3%)
6 (20.0%)
0
1 (3.3%) .301*
0
1 (3.3%)
0
9 (30.0%) .417*
6 (20.0%)
0
4 (13.3%)
6 (20.0%) .488*
0
1 (3.3%)
5 (16.7%)
0
22 (73.3%) 1.000*
0
10 (33.3%)
1 (3.3%)
2 (6.7%)
1 (3.3%)
2 (6.7%)
10 (33.3%)
0
9 (30.0%)
15 (50.0%)
2 (6.7%)
3 (10.0%) 1.000†
1 (3.3%)
1 (3.3%)
2 (6.7%)
23 (76.7%) 1.000*
13 (43.3%)
16 (53.3%)
22 (73.3%)
17 (56.7%)
splant toxicity between BuCy and BuFluATG regimens.MT
(n 
0
43.3%)
26.7%)
40.0%)
10.0%)
0
0
36.7%)
10.0%)
23.3%)
1
10.0%)
3.3%)
3.3%)
3.3%)
40.0%)
13.3%)
30.0%)
0
13.3%)
3.3%)
3.3%)
6.7%)
6.7%)
73.3%)
0
43.3%)
0
6.7%)
3.3%)
6.7%)
46.7%)
3.3%)
46.7%)
43.3%)
3.3%)
10.0%)
10.0%)
0
3.3%)
76.7%)
46.7%)
60.0%)
76.7%)
56.7%)
osttranhe 2 conditioning regimens (BuCy or BuFluATG),
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S.-G. Ryu et al.1102e performed subset analyses according to these reg-
mens. Subset analyses revealed that nonrelapse mor-
ality and overall survival were not signiﬁcantly differ-
nt between the BU1 and BU4 arms (Table 6).
ISCUSSION
Because busulfan is not cell cycle-nonspeciﬁc
ike other alkylating agents, frequent dosing or con-
inuous infusion is not necessary to increase its
ffectiveness. Thus, it is reasonable to administer
usulfan on a daily basis if there is no association
ith excessive toxicity. Several single-arm studies
uggest that once-daily or twice-daily intravenous
dministration of high doses of busulfan do not
ncrease posttransplant toxicity, compared to the
raditional 4-times-daily schedule [21,25,26]. In our
andomized trial, nonrelapse mortality and early post-
ransplant toxicities were not signiﬁcantly different
etween the once-daily and 4-times-daily regimens of
ntravenous busulfan. There were 4 nonrelapse deaths
mong 30 patients in both arms within 100 days after
CT. Although 2 of the nonrelapse deaths in the
nce-daily arm were ascribed to secondary graft fail-
re, no major differences in engraftment data were
vident between the 2 schedules. Additionally, the
umulative incidence of acute GVHD was similar be-
ween the 2 treatment schedules. The frequency of
epatic VOD was low in both arms, and no severe
OD was observed. This ﬁnding was expected, be-
ause previous retrospective comparisons, including
ur experience, showed that use of intravenous instead
f oral busulfan resulted in a lower frequency of he-
atic VOD and related deaths [37-39]. The low inci-
ence of hepatic VOD with intravenous busulfan may
Figure 2. Overall survival of the BU4 and BU1 arms.e because of avoidance of erratic absorption and tepatic ﬁrst-pass effect of oral busulfan [12,37,39].
evere posttransplant toxicities (deﬁned as NCI
rades III to IV) within 100 days after HCT were also
omparable between the 2 administration schedules.
xcessive exposure to busulfan may be associated with
entral nervous system toxicity [40]. In our study,
evere neurologic toxicity was infrequent in both
rms, and did not appear to be directly related to
usulfan, because the time interval between the oc-
urrence of severe neurologic toxicity and busulfan
dministration was 30 days. Phenytoin, adminis-
ered to all patients during busulfan treatment, effec-
ively prevented seizure development. Our results
emonstrate that once-daily administration of intra-
enous busulfan, leading to a higher plasma peak con-
entration, has similar effects on engraftment of he-
atopoietic cells, and does not augment tissue injury
o lung, kidney, heart, liver, and central nervous sys-
em after HCT, compared to traditional 4-times-daily
dministration.
Previous reports demonstrate that intravenous
usulfan yields reproducible and predictable pharma-
okinetics with less interdose and interpatient variabil-
ty than oral busulfan [19,21,25,26]. The studies also
uggest that once- or twice-daily administration of
ntravenous busulfan may yield similar pharmacoki-
etic parameters and toxicity proﬁles to the traditional
-times-daily dosing. In a phase I study, the median
UC of busulfan in 5 patients who received intrave-
ous busulfan dose of 0.8 mg/kg was 1132 M·min
range: 964-1547 M·min) and the AUC and other
harmacokinetic parameters at that dose were similar
o those from oral busulfan dose of 1.0 mg/kg [19].
ntravenous busulfan (total daily dose of 3.2 mg/kg)
as evaluated its safety and pharmacokinetics with a
igure 3. Nonrelapse mortality of patients in the BU4 and Bu1
reatment groups.
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Four-Times Daily versus Once-Daily Intravenous Busulfan 1103wice-daily or once-daily schedule in a BuCy regimen.
n the study, the median AUC of busulfan was 3390
M·min (range: 2400-4678 M·min) in 6 patients
ith twice-daily schedule and 5561 M·min (range:
414-7368 M·min) in other 6 patients with once-
aily schedule [21]. The study suggested that the
hange in dosing schedule did not increase toxicity or
nd-organ damage despite higher plasma concentra-
ion times. Two other studies investigated the safety
f once-daily intravenous busulfan (3.2 mg/kg/day or
30 mg/m2/day) plus ﬂudarabine as conditioning for
llogeneic HCT. The median AUC of busulfan was
973 M·min (range: 3432-6244 M·min) with intra-
enous busulfan dose of 3.2 mg/kg/day (n  12) [26]
nd was 4871 M·min (range: 2931-8271 M·min)
ith 130 mg/m2/day dose (n  45) [25]. Both studies
howed that once-daily intravenous busulfan was well
olerated and did not increase toxicities. As evidence-
ased medicine requires randomized comparison and
e designed a prospective randomized trial comparing
nce-daily versus traditional 4-times-daily intravenous
usulfan. In our study, both once-daily and 4-times-
aily administration of intravenous busulfan led to
redictable linear kinetics with little interpatient vari-
bility, as reﬂected by a CV of 20% or less in all
harmacokinetic parameters, such as Vd, half-life,
learance, and estimated daily AUC. Moreover, these
arameters were comparable between the 2 dosage
chedules. The Cmax the once-daily arm was about 4
imes that of the 4-times-daily arm, as expected, but
id not affect toxicity, at least in the concentration
ange of 0.8 to 3.2 mg/kg of intravenous busulfan.
hese ﬁndings are consistent with previous results,
hich disclose the importance of AUC or steady-state
lasma concentrations, rather than peak concentra-
ions, for posttransplant toxicity and effectiveness [11-
4,21,25,26]. Our pharmacokinetic results clearly sug-
est that once-daily and traditional 4-times-daily
ntravenous busulfan are equally effective, in view of
able 6. Nonrelapse Mortality and Overall Survival
Overall Survival*
100 Days†
ll patients
Bu4 arm (n  30) 86.7% (74.5-98.9%) 69.0%
Bu1 arm (n  30) 86.7% (74.5-98.9%) 70.0%
uCy regimen
Bu4 arm (n  12) 83.3% (62.2-100%) 64.3%
Bu1 arm (n  13) 92.3% (77.8-100%) 69.2%
uFluATG regimen
Bu4 arm (n  17) 88.2% (729-100%) 70.6%
Bu1 arm (n  16) 81.3% (62.2-100%) 75.0%
Kaplan-Meier method, survival probability (95% conﬁdence inter
Posttransplant.
Calculation of cumulative incidence, cumulative incidence (95% c
in the Bu1 arm.he comparable estimated daily AUC between the 2 tchedules. Although our randomized study conﬁrmed
he safety of once-daily intravenous busulfan, further
tudy for long-term efﬁcacy should be performed. In
ur study, the estimated daily AUC was higher, al-
hough statistically not signiﬁcant, in once-daily dos-
ng than 4-times-daily dosing. The potential clinical
mpact of such differences should also be further in-
estigated.
Once-daily administration of intravenous busulfan
as several advantages over the traditional schedule.
irst, once-daily dosing is more tolerable and conve-
ient for both carers and patients, compared to more
requent dosing. The chances of administration errors
ay also be lower. Second, less frequent administra-
ion of intravenous busulfan makes it possible to per-
orm transplantation procedures in the outpatient set-
ing. Third, our studies, in conjunction with other
eports, show that intravenous busulfan (0.8-3.2 mg/
g) displays linear pharmacokinetics. Thus, a more
onsistent systemic exposure of intravenous busulfan
s predicted with the once-daily dosage schedule be-
ause of no drug accumulation from 1 dose to the
ext. Fourth, single administration leads to a higher
eak of busulfan concentration than divided dosing,
nd thus better penetration of poorly vascularized
sanctuary sites.” Fifth, the once-daily schedule may
ave some theoretic advantages over 4-times-daily ad-
inistration regarding hepatic VOD, since glutathio-
e-S-reductase and glutathione-S-transferase recov-
ry between doses is more viable with the once-daily
pproach [21]. Moreover, the time separation between
he last dose of busulfan and ﬁrst dose of cyclophos-
hamide in the BuCy regimen may contribute to a
eduction in hepatic injury [9,14].
Pharmacokinetic studies on oral busulfan show
hat systemic drug exposure is related to clinical out-
ome after HCT. Low plasma busulfan concentration
s associated with relapse of underlying disease [13] or
raft rejection [41], whereas high plasma concentra-
Nonrelapse Mortality‡
† 100 Days† 2 Years†
86.0%) 13.3% (5.4-33.2%) 20.8% (10.1-42.6%)
86.4%) 13.3% (5.4-33.2%) 13.3% (5.4-33.2%)
92.9%) 16.7% (4.7-59.1%) 27.4% (10.3-73.0%)
94.3%) 7.7% (1.2-50.6%) 7.7% (1.2-50.6%)
92.3%) 11.8% (3.2-43.3%) 17.7% (6.3-49.3%)
96.2%) 18.8% (6.8-52.0%) 18.8% (6.8-52.0%)
ce interval); number of nonrelapse deaths: 7 in the Bu4 arm and 41 Year
(52.0-
(53.6-
(35.7-
(44.1-
(48.9-
(53.8-
val).
onﬁdenion is associated with the occurrence of hepatic VOD
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S.-G. Ryu et al.110411,12] or nonrelapse mortality [42]. These ﬁndings
ave led to the development of individualized dose
djustment strategy [43], which targets the oral busul-
an dose to the predetermined plasma level after a test
ose. The low interdose variability of intravenous
usulfan makes it more possible to adjust the concen-
ration after a test dose or the ﬁrst therapeutic dose,
ompared to oral busulfan [44]. Systemic exposure of
ntravenous busulfan is also related to posttransplant
utcomes in patients with chronic myeloid leukemia
45]. However, considering the low interpatient variabil-
ty of the pharmacokinetic parameters of intravenous
usulfan, it is questionable whether more precise deliv-
ry of the appropriated quantity of intravenous busulfan
y pharmacokinetics-guided individualized dosing
ould improve posttransplant outcomes (toxicities
nd/or effects). Our group and others [21,25,26] showed
hat the pharmacokinetic parameters of intravenous
usulfan are within the 2-fold range, similar to that by
argeted oral busulfan. The optimal AUC range for in-
ravenous busulfan remains to be determined. Further-
ore, a plasma busulfan concentration assay is not
eadily available in most clinical settings. It may be more
easible to identify the variables that have a signiﬁcant
nﬂuence on the pharmacokinetic parameters of intrave-
ous busulfan, and develop an optimal dose calculation
ethod to deliver more precise quantities of the drug.
pharmacogenomic approach may be additionally
equired [46].
In conclusion, our randomized study demonstrates
hat once-daily intravenous busulfan has similar phar-
acokinetic proﬁles and posttransplant complications
s the traditional 4-times-daily administered drug. In
iew of the theoretic advantages and convenience, we
ecommend the once-daily administration schedule
or the use of intravenous busulfan as conditioning
herapy prior to HCT.
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